Note 15 - Segments (Tables)

9 Months Ended

Sep. 30, 2019

Three Months Ended September 30 , 2019	Diagnostics			Therapeutics		Corporate			Total
Royalty revenue	$	4,895		$	—	$	—		$	4,895
Grant and other revenue		77,049			154,867		—			231,916
Total revenue		81,944			154,867		—			236,811
Cost of revenue		195			—		—			195
Research and development expenses		1,678,423			123,135		—			1,801,558
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			1,052		1,484,155			1,485,207
Depreciation and amortization (2)		—			—		34,289			34,289
(Loss) income from operations (3)		(1,596,674	)		30,680		(1,518,444	)		(3,084,438	)
Other income (4)		—			—		10,334			10,334
Income tax (expense) benefit		(72	)		16		55			—
Net (loss) income		(1,596,746	)		30,696		(1,508,055	)		(3,074,104	)
Total assets, net of depreciation and amortization:
United States	$	36,811		$	93,860	$	4,688,379		$	4,819,050
International		2,606			—		—			2,606
Capital expenditures		—			—		—			—

T hree Months Ended September 30, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	2,382		$	—		$	—		$	2,382
License revenue		19,930			—			—			19,930
Grant and other revenue		65,505			143,641			—			209,146
Total revenue		87,817			143,641			—			231,458
Cost of revenue		38,101			—			—			38,101
Research and development expenses		711,355			514,415			—			1,225,770
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			20,532			2,630,581			2,651,113
Depreciation and amortization (2)		—			—			37,590			37,590
Loss from operations (3)		(661,639	)		(391,306	)		(2,668,171	)		(3,721,116	)
Other expense (4)		—			—			(24,534	)		(24,534	)
Income tax expense		(10,081	)		(3,879	)		(62,299	)		(76,259	)
Net loss		(671,720	)		(395,185	)		(2,755,004	)		(3,821,909	)
Total assets, net of depreciation and amortization:
United States	$	117,722		$	72,622		$	8,899,301		$	9,089,645
International		18,239			—			1,158			19,397
Capital expenditures		—			—			16,152			16,152

Nine Months Ended September 30, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	13,985		$	—		$	—		$	13,985
License revenue		9,953			—			—			9,953
Grant and other revenue		309,670			204,919			—			514,589
Total revenue		333,608			204,919			—			538,527
Cost of revenue		6,559			—			—			6,559
Research and development expenses		3,194,468			418,315			—			3,612,783
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			15,828			4,985,990			5,001,818
Depreciation and amortization (2)		—			—			107,794			107,794
Loss from operations (3)		(2,867,419	)		(229,224	)		(5,093,784	)		(8,190,427	)
Other income (4)		—			—			17,456			17,456
Provision for income tax		(248	)		(20	)		(439	)		(707	)
Net loss from continuing operations		(2,867,667	)		(229,244	)		(5,076,767	)		(8,173,678	)
Loss from discontinued operations, net of tax		(2,665	)		—			—			(2,665	)
Net loss		(2,870,332	)		(229,244	)		(5,076,767	)		(8,176,343	)
Total assets, net of depreciation and amortization:
United States	$	36,811		$	93,860		$	4,688,379		$	4,819,050
International		2,606			—			—			2,606
Capital expenditures		—			—			—			—

Nine Months Ended September 30, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	9,842		$	—		$	—		$	9,842
License revenue		277,639			—			—			277,639
Grant and other revenue		454,830			307,719			—			762,549
Total revenue		742,311			307,719			—			1,050,030
Cost of revenue		73,811			—			—			73,811
Research and development expenses		2,409,524			957,920			—			3,367,444
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			45,769			6,095,617			6,141,386
Depreciation and amortization (2)		—			—			113,088			113,088
Loss from operations (3)		(1,741,024	)		(695,970	)		(6,208,705	)		(8,645,699	)
Other expense (4)		—			—			(4,284,014	)		(4,284,014	)
Income tax expense		(8,797	)		(3,517	)		(53,017	)		(65,330	)
Net loss from continuing operations		(1,749,821	)		(699,487	)		(10,545,736	)		(12,995,043	)
Loss from discontinued operations, net of tax		(1,938	)		—			—			(1,938	)
Gain on sale of discontinued operations, net of tax		43,053			—			—			43,053
Net loss		(1,708,706	)		(699,487	)		(10,545,736	)		(12,953,928	)
Total assets, net of depreciation and amortization:
United States	$	117,722		$	72,622		$	8,899,301		$	9,089,645
International		18,239			—			1,158			19,397
Capital expenditures		—			—			19,317			19,317